BidaskClub Lowers VBI Vaccines (VBIV) to Sell
BidaskClub downgraded shares of VBI Vaccines (NASDAQ:VBIV) from a hold rating to a sell rating in a research note released on Saturday.
Several other equities research analysts have also commented on VBIV. Zacks Investment Research raised shares of VBI Vaccines from a sell rating to a hold rating in a report on Tuesday, September 26th. Canaccord Genuity started coverage on shares of VBI Vaccines in a report on Wednesday, November 1st. They issued a buy rating and a $10.00 price target for the company. Finally, BMO Capital Markets started coverage on shares of VBI Vaccines in a report on Wednesday, November 15th. They issued an outperform rating and a $11.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. VBI Vaccines has an average rating of Hold and a consensus price target of $8.75.
Shares of VBI Vaccines (NASDAQ:VBIV) traded up $0.05 during midday trading on Friday, reaching $4.19. 97,760 shares of the company traded hands, compared to its average volume of 111,525. The company has a quick ratio of 0.97, a current ratio of 1.03 and a debt-to-equity ratio of 0.19. VBI Vaccines has a 12 month low of $3.04 and a 12 month high of $6.60.
In other VBI Vaccines news, Director Steven Gillis bought 300,000 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was acquired at an average price of $3.05 per share, with a total value of $915,000.00. Following the completion of the acquisition, the director now directly owns 46,916 shares of the company’s stock, valued at $143,093.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeff Baxter bought 10,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were acquired at an average cost of $3.89 per share, with a total value of $38,900.00. Following the acquisition, the chief executive officer now directly owns 140,646 shares of the company’s stock, valued at $547,112.94. The disclosure for this purchase can be found here. Insiders have bought 4,080,738 shares of company stock valued at $12,480,151 in the last ninety days. Insiders own 54.50% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new stake in shares of VBI Vaccines during the second quarter worth $167,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of VBI Vaccines during the second quarter worth $187,000. Bank of New York Mellon Corp purchased a new stake in shares of VBI Vaccines during the second quarter worth $193,000. Teachers Advisors LLC purchased a new stake in shares of VBI Vaccines during the second quarter worth $195,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in shares of VBI Vaccines during the second quarter worth $262,000. 20.93% of the stock is owned by institutional investors and hedge funds.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.